Science & Technology

Novel Theranostic Radioligands Targeting Disease-Specific Extracellular Matrix Components Specific to Tumor and Metastatic Lesions in Patients Suffering From Hereditary Breast and Ovarian Cancer (Hboc

Department of Health and Human Services — National Institutes of Health

Opportunity #: 75N91025C00039

Award Ceiling

$354K

Award Floor

$354K

Close Date

N/A

Total Funding

$354K

Expected Awards

Cost Sharing Required

Grants.gov ID

sbir-75N91025C00039

Description

SBIR Phase Phase I award: "NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOC" awarded to MATRISOME BIO, INC. in WILMINGTON, Delaware. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $354,456. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.

Eligible Applicants

Small businesses, Women-owned businesses

Apply on Grants.gov

Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.

View on Grants.gov

Disclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.